메뉴 건너뛰기




Volumn 29, Issue 7, 2014, Pages 1463-1469

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study

Author keywords

First line therapy; Liver neoplasm; Prognosis; Safety; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; TUMOR MARKER;

EID: 84904355176     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12542     Document Type: Article
Times cited : (28)

References (31)
  • 1
    • 0033545541 scopus 로고    scopus 로고
    • Rising incidence of hepatocellular carcinoma in the United States
    • El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999; 340: 745-750.
    • (1999) N. Engl. J. Med. , vol.340 , pp. 745-750
    • El-Serag, H.B.1    Mason, A.C.2
  • 4
    • 79952231921 scopus 로고    scopus 로고
    • Management of hepatocellular carcinoma: an update
    • Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
    • (2011) Hepatology , vol.53 , pp. 1020-1022
    • Bruix, J.1    Sherman, M.2
  • 5
    • 84871830149 scopus 로고    scopus 로고
    • How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage
    • Kim do Y, Han KH. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. Dig. Dis. 2012; 30: 598-602.
    • (2012) Dig. Dis. , vol.30 , pp. 598-602
    • Kim do, Y.1    Han, K.H.2
  • 6
    • 52049096005 scopus 로고    scopus 로고
    • Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis
    • Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
    • (2008) Cancer , vol.113 , pp. 995-1003
    • Han, K.H.1    Seong, J.2    Kim, J.K.3    Ahn, S.H.4    Lee do, Y.5    Chon, C.Y.6
  • 7
    • 34250888086 scopus 로고    scopus 로고
    • Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma
    • Park JY, Ahn SH, Yoon YJ etal. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-137.
    • (2007) Cancer , vol.110 , pp. 129-137
    • Park, J.Y.1    Ahn, S.H.2    Yoon, Y.J.3
  • 8
    • 4944249117 scopus 로고    scopus 로고
    • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • Wilhelm SM, Carter C, Tang L etal. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-7109.
    • (2004) Cancer Res. , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1    Carter, C.2    Tang, L.3
  • 9
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    • Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
    • (2009) Lancet Oncol. , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3
  • 10
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-390.
    • (2008) N. Engl. J. Med. , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 11
    • 84864794559 scopus 로고    scopus 로고
    • Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib
    • Kawaoka T, Aikata H, Murakami E etal. Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology 2012; 83: 192-200.
    • (2012) Oncology , vol.83 , pp. 192-200
    • Kawaoka, T.1    Aikata, H.2    Murakami, E.3
  • 12
    • 84872771082 scopus 로고    scopus 로고
    • Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma
    • Lee JH, Chung YH, Kim JA etal. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013; 119: 136-142.
    • (2013) Cancer , vol.119 , pp. 136-142
    • Lee, J.H.1    Chung, Y.H.2    Kim, J.A.3
  • 13
    • 84862776834 scopus 로고    scopus 로고
    • Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma
    • Kim JE, Ryoo BY, Ryu MH etal. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology 2012; 82: 119-125.
    • (2012) Oncology , vol.82 , pp. 119-125
    • Kim, J.E.1    Ryoo, B.Y.2    Ryu, M.H.3
  • 14
    • 84868605784 scopus 로고    scopus 로고
    • Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma
    • Nakano M, Tanaka M, Kuromatsu R etal. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology 2013; 84: 108-114.
    • (2013) Oncology , vol.84 , pp. 108-114
    • Nakano, M.1    Tanaka, M.2    Kuromatsu, R.3
  • 15
    • 75349086029 scopus 로고    scopus 로고
    • Practice guidelines for management of hepatocellular carcinoma 2009
    • Korean Liver Cancer Study Group and National Cancer Center.
    • Korean Liver Cancer Study Group and National Cancer Center. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J. Hepatol. 2009; 15: 391-423.
    • (2009) Korean J. Hepatol. , vol.15 , pp. 391-423
  • 16
    • 84855174099 scopus 로고    scopus 로고
    • Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion
    • Chun YH, Ahn SH, Park JY etal. Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. Anticancer Res. 2011; 31: 4641-4646.
    • (2011) Anticancer Res. , vol.31 , pp. 4641-4646
    • Chun, Y.H.1    Ahn, S.H.2    Park, J.Y.3
  • 17
    • 54949157603 scopus 로고    scopus 로고
    • Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors
    • Kim SU, Kim Y, Park JY etal. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J. Cancer Res. Clin. Oncol. 2008; 134: 1377-1384.
    • (2008) J. Cancer Res. Clin. Oncol. , vol.134 , pp. 1377-1384
    • Kim, S.U.1    Kim, Y.2    Park, J.Y.3
  • 18
    • 75649116842 scopus 로고    scopus 로고
    • Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    • Vincenzi B, Santini D, Russo A etal. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92.
    • (2010) Oncologist , vol.15 , pp. 85-92
    • Vincenzi, B.1    Santini, D.2    Russo, A.3
  • 19
    • 79959421984 scopus 로고    scopus 로고
    • Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models
    • Baek KK, Kim JH, Uhm JE etal. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011; 80: 167-174.
    • (2011) Oncology , vol.80 , pp. 167-174
    • Baek, K.K.1    Kim, J.H.2    Uhm, J.E.3
  • 20
    • 67651095716 scopus 로고    scopus 로고
    • Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis
    • Worns MA, Weinmann A, Pfingst K etal. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 2009; 43: 489-495.
    • (2009) J. Clin. Gastroenterol. , vol.43 , pp. 489-495
    • Worns, M.A.1    Weinmann, A.2    Pfingst, K.3
  • 21
    • 33749017926 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    • Abou-Alfa GK, Schwartz L, Ricci S etal. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006; 24: 4293-4300.
    • (2006) J. Clin. Oncol. , vol.24 , pp. 4293-4300
    • Abou-Alfa, G.K.1    Schwartz, L.2    Ricci, S.3
  • 22
    • 84862737988 scopus 로고    scopus 로고
    • First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study
    • Lencioni R, Kudo M, Ye SL etal. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int. J. Clin. Pract. 2012; 66: 675-683.
    • (2012) Int. J. Clin. Pract. , vol.66 , pp. 675-683
    • Lencioni, R.1    Kudo, M.2    Ye, S.L.3
  • 23
    • 84867871965 scopus 로고    scopus 로고
    • The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits
    • Chiu J, Tang YF, Yao TJ etal. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012; 118: 5293-5301.
    • (2012) Cancer , vol.118 , pp. 5293-5301
    • Chiu, J.1    Tang, Y.F.2    Yao, T.J.3
  • 24
    • 45749152254 scopus 로고    scopus 로고
    • Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients
    • Saif MW, Merikas I, Tsimboukis S, Syrigos K. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 2008; 9: 267-274.
    • (2008) JOP , vol.9 , pp. 267-274
    • Saif, M.W.1    Merikas, I.2    Tsimboukis, S.3    Syrigos, K.4
  • 25
    • 84884288905 scopus 로고    scopus 로고
    • The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials
    • Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target. Oncol. 2013; 8: 173-181.
    • (2013) Target. Oncol. , vol.8 , pp. 173-181
    • Petrelli, F.1    Borgonovo, K.2    Barni, S.3
  • 26
    • 80955142670 scopus 로고    scopus 로고
    • A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors
    • Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur. J. Gastroenterol. Hepatol. 2011; 23: 1233-1238.
    • (2011) Eur. J. Gastroenterol. Hepatol. , vol.23 , pp. 1233-1238
    • Song, T.1    Zhang, W.2    Wu, Q.3    Kong, D.4    Ma, W.5
  • 27
    • 84867464777 scopus 로고    scopus 로고
    • Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma
    • Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 2013; 84: 6-13.
    • (2013) Oncology , vol.84 , pp. 6-13
    • Koschny, R.1    Gotthardt, D.2    Koehler, C.3    Jaeger, D.4    Stremmel, W.5    Ganten, T.M.6
  • 28
    • 84859722049 scopus 로고    scopus 로고
    • Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis
    • Memon K, Kulik L, Lewandowski RJ etal. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J. Hepatol. 2012; 56: 1112-1120.
    • (2012) J. Hepatol. , vol.56 , pp. 1112-1120
    • Memon, K.1    Kulik, L.2    Lewandowski, R.J.3
  • 29
    • 84877011264 scopus 로고    scopus 로고
    • Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
    • Nakazawa T, Hidaka H, Takada J etal. Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur. J. Gastroenterol. Hepatol. 2013; 25: 683-689.
    • (2013) Eur. J. Gastroenterol. Hepatol. , vol.25 , pp. 683-689
    • Nakazawa, T.1    Hidaka, H.2    Takada, J.3
  • 30
    • 57349090407 scopus 로고    scopus 로고
    • Gene expression in fixed tissues and outcome in hepatocellular carcinoma
    • Hoshida Y, Villanueva A, Kobayashi M etal. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 1995-2004.
    • (2008) N. Engl. J. Med. , vol.359 , pp. 1995-2004
    • Hoshida, Y.1    Villanueva, A.2    Kobayashi, M.3
  • 31
    • 84859393351 scopus 로고    scopus 로고
    • Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival
    • 957-66 e12
    • Roessler S, Long EL, Budhu A etal. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2012; 142: 957-66 e12.
    • (2012) Gastroenterology , vol.142
    • Roessler, S.1    Long, E.L.2    Budhu, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.